fenofibrate has been researched along with Hypercholesterolemia in 93 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to determine whether a short-term treatment with simvastatin or fenofibrate may result in beneficial anti-inflammatory and antithrombotic effects in patients with high risk of coronary artery disease." | 9.11 | Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. ( Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A, 2005) |
| "This double-blind study was designed to assess the efficacy and safety of fluvastatin-fenofibrate combination therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol > or =190 mg/dl [4." | 9.09 | Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. ( Dejager, S; Farnier, M, 2000) |
| "This multicenter, double-blind, randomized study was designed to compare the effects of simvastatin (20 mg/d and 40 mg/d) and fenofibrate (400 mg/d) on plasma lipids, lipoproteins, apolipoproteins (apo), and lipoprotein particles defined by their apo composition (Lp A-I, Lp A-II:A-I, Lp E:B, Lp C-III:B) in primary hypercholesterolemia." | 9.07 | A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. ( Bard, JM; Bruckert, E; Camare, R; Dachet, C; Douste-Blazy, P; Drouin, P; Jacotot, B; Luc, G; Parra, HJ; Ziegler, O, 1992) |
| "The effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia were assessed in a 6-month parallel group study, placebo (n = 15) versus fenofibrate 300 mg/day (n = 18), followed by an open label 6-month treatment period." | 9.06 | Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. ( Glueck, CJ; Khoury, P; Lamkin, G; Mellies, MJ; Stein, EA, 1987) |
| "The effects of simvastatin and fenofibrate on blood lipids and the side-effects of these two drugs were compared in a double-blind trial involving 184 adults with primary hypercholesterolemia (total cholesterol levels: 3." | 9.06 | [The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia]. ( Dachet, C; De Gennes, JL; Douste-Blazy, P; Drouin, P; Fricker, J; Keller, U, 1990) |
| " The aim of this study was to investigate the effect of two different treatment periods of fenofibrate (CAS 49562-28-9) on serum, heart and liver sialic acid levels in experimental hypercholesterolemia." | 7.74 | Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia. ( Emekli, N; Oztürk, LK; Yarat, A, 2007) |
| "To report a case of probable fenofibrate-induced gynecomastia." | 7.74 | Gynecomastia associated with fenofibrate. ( Gardette, V; Maiza, JC; Montastruc, JL; Olivier, P; Vezzosi, D, 2007) |
| "Effects of bifendate, a synthetic intermediate of schisandrin C (a dibenzocyclooctadiene derivative), on liver lipid contents were investigated in experimentally-induced hypercholesterolemia in mice." | 7.73 | Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. ( Dong, H; Ko, KM; Pan, SY; Yang, R; Yu, ZL, 2006) |
| " We studied whether adipocytes could uptake and degrade OxLDL through CD36 and explored the effect of fenofibrate on OxLDL uptake in adipocytes from hypercholesterolemia rabbits." | 7.72 | Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit. ( Li, JQ; Liu, L; Wu, J; Ye, HJ; Zhang, DQ; Zhao, SP, 2004) |
| " Safety was evaluated based on data collected for adverse events (AEs), physical and electrocardiographic examinations, vital sign measurements, and clinical laboratory tests." | 6.75 | Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. ( Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| " There were no major clinical or biological adverse events in the dose interval from 200 mg to 400 mg of micronised fenofibrate per day." | 6.69 | Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. ( Corda, C; Farnier, M; Gerlinger, C; Issa-Sayegh, M; Krempf, M; Masseyeff-Elbaz, MF; Rohmer, V; Sirugue, I, 2000) |
| " Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose." | 5.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 5.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| "Rhabdomyolysis is one of the side effects of these drugs." | 5.31 | [Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate]. ( Dabrowska, M; Duda-Król, W; Jórasz, I; Kusz-Rynkun, A; Polubiec, A, 2000) |
| " Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone." | 5.22 | Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. ( Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF, 2016) |
| "Dyslipidemia study: placebo, fenofibrate (200 mg), or LY518674 (10, 25, 50, or 100 microg) for 12 weeks." | 5.12 | Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. ( Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K, 2007) |
| "The cholesterol absorption inhibitor, ezetimibe, significantly decreases low-density lipoprotein-cholesterol (LDL-C) levels in patients with primary hypercholesterolemia." | 5.11 | Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. ( Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004) |
| "The aim of the study was to determine whether a short-term treatment with simvastatin or fenofibrate may result in beneficial anti-inflammatory and antithrombotic effects in patients with high risk of coronary artery disease." | 5.11 | Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. ( Celinska-Löwenhoff, M; Domagala, TB; Dropinski, J; Iwaniec, T; Löwenhoff, T; Szczeklik, A; Undas, A, 2005) |
| "Diabetic subjects with mild hypercholesterolemia and good glycemic control may benefit from therapy with micronised fenofibrate because of the reduction in serum triglyceride, elevation in HDL cholesterol and a shift in LDL subfraction towards a non-atherogenic form." | 5.09 | Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. ( Chew, LS; Chio, LF; Lim, HS; Loh, LM; Shepherd, J; Tai, ES; Tan, CE, 2001) |
| "This double-blind study was designed to assess the efficacy and safety of fluvastatin-fenofibrate combination therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia (low-density lipoprotein [LDL] cholesterol > or =190 mg/dl [4." | 5.09 | Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group. ( Dejager, S; Farnier, M, 2000) |
| "This multicenter, double-blind, randomized study was designed to compare the effects of simvastatin (20 mg/d and 40 mg/d) and fenofibrate (400 mg/d) on plasma lipids, lipoproteins, apolipoproteins (apo), and lipoprotein particles defined by their apo composition (Lp A-I, Lp A-II:A-I, Lp E:B, Lp C-III:B) in primary hypercholesterolemia." | 5.07 | A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. ( Bard, JM; Bruckert, E; Camare, R; Dachet, C; Douste-Blazy, P; Drouin, P; Jacotot, B; Luc, G; Parra, HJ; Ziegler, O, 1992) |
| "This study compares the effects of fenofibrate and simvastatin in primary hypercholesterolemia, with particular regard to lipoprotein particles, as defined by their apolipoprotein composition: LpAI, LpAII: AI, LpE:B, LpCIII:B." | 5.07 | Lipoprotein particle analysis comparing simvastatin and fenofibrate. ( Bard, JM; Bruckert, E; Camare, R; Dachet, C; Douste-Blazy, P; Drouin, P; Jacotot, B; Luc, G; Parra, HJ; Ziegler, O, 1991) |
| "The effects of simvastatin and fenofibrate on blood lipids and the side-effects of these two drugs were compared in a double-blind trial involving 184 adults with primary hypercholesterolemia (total cholesterol levels: 3." | 5.06 | [The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia]. ( Dachet, C; De Gennes, JL; Douste-Blazy, P; Drouin, P; Fricker, J; Keller, U, 1990) |
| "The effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia were assessed in a 6-month parallel group study, placebo (n = 15) versus fenofibrate 300 mg/day (n = 18), followed by an open label 6-month treatment period." | 5.06 | Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. ( Glueck, CJ; Khoury, P; Lamkin, G; Mellies, MJ; Stein, EA, 1987) |
| "To report a case of probable fenofibrate-induced gynecomastia." | 3.74 | Gynecomastia associated with fenofibrate. ( Gardette, V; Maiza, JC; Montastruc, JL; Olivier, P; Vezzosi, D, 2007) |
| "Fenofibrate has shown to reduce major cardiovascular events and slow angiographic progression of coronary atherosclerosis." | 3.74 | Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. ( Badimon, JJ; Corti, R; Fallon, JT; Fuster, V; Hutter, R; Mizsei, G; Osende, J; Valdivieso, C; Viles-Gonzalez, JF; Zafar, U, 2007) |
| " The aim of this study was to investigate the effect of two different treatment periods of fenofibrate (CAS 49562-28-9) on serum, heart and liver sialic acid levels in experimental hypercholesterolemia." | 3.74 | Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia. ( Emekli, N; Oztürk, LK; Yarat, A, 2007) |
| "Effects of bifendate, a synthetic intermediate of schisandrin C (a dibenzocyclooctadiene derivative), on liver lipid contents were investigated in experimentally-induced hypercholesterolemia in mice." | 3.73 | Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. ( Dong, H; Ko, KM; Pan, SY; Yang, R; Yu, ZL, 2006) |
| "Five patients (median age 68 [54-78], female N =4) with CLD treatment (statin N =4, fenofibrates N =1) have developed iatrogenic polymyositis." | 3.72 | [Polymyositis induced or associated with lipid-lowering drugs: five cases]. ( Bataille, D; Devulder, B; Fauchais, AL; Hachulla, E; Hatron, PY; Iba Ba, J; Kyndt, X; Lambert, M; Maurage, P; Michon Pasturel, U; Parent, D; Queyrel, V; Vanhille, P, 2004) |
| " Fenofibrate treatment did not change serum lipid levels during the feeding period, but decreased high cholesterol diet-induced increases in body weight by 19% and serum TNF-alpha concentration by 44." | 3.72 | Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. ( Wu, J; Zhao, SP, 2004) |
| " We studied whether adipocytes could uptake and degrade OxLDL through CD36 and explored the effect of fenofibrate on OxLDL uptake in adipocytes from hypercholesterolemia rabbits." | 3.72 | Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit. ( Li, JQ; Liu, L; Wu, J; Ye, HJ; Zhang, DQ; Zhao, SP, 2004) |
| "150 patients suffering from primary hypercholesterolemia were divided into three different groups receiving (1) lovastatin, (2) simvastatin, or (3) fenofibrate as controls." | 3.69 | Ocular drug safety and HMG-CoA-reductase inhibitors. ( Hockwin, O; Paulus, U; Schmidt, J; Schmitt, C; von Bergmann, K, 1994) |
| " Every-4-weeks dosing of alirocumab may be appropriate for some patients in absence of background statin but is not yet approved." | 2.82 | Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. ( Brunet, A; Cannon, CP; DiCioccio, AT; Hanotin, C; Paehler, T; Pinquier, JL; Poitiers, F; Rey, J; Sasiela, WJ; Surks, HK, 2016) |
| " Safety was evaluated based on data collected for adverse events (AEs), physical and electrocardiographic examinations, vital sign measurements, and clinical laboratory tests." | 2.75 | Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. ( Carlson, DM; Gold, A; Jones, PH; Kelly, MT; McKenney, JM; Roth, EM; Setze, CM; Stolzenbach, JC; Williams, LA, 2010) |
| " There were no major clinical or biological adverse events in the dose interval from 200 mg to 400 mg of micronised fenofibrate per day." | 2.69 | Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia. ( Corda, C; Farnier, M; Gerlinger, C; Issa-Sayegh, M; Krempf, M; Masseyeff-Elbaz, MF; Rohmer, V; Sirugue, I, 2000) |
| " This short-term study showed few adverse effects for both drugs." | 2.67 | Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. ( Bonnefous, F; Debbas, N; Farnier, M; Irvine, A, 1994) |
| "Large randomized clinical trials are currently under way to test the cardiovascular benefits of omega-3 fatty acids at a pharmacologic dosage (4 g/day)." | 2.61 | New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease. ( Preston Mason, R, 2019) |
| "Hypercholesterolemia can induce xanthomas of the Achilles tendons." | 2.44 | [Involvement of the foot in metabolic diseases]. ( Gerster, JC, 2007) |
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| "Fenofibrate is a fibric acid derivative that has been available in much of the world for over 10 years." | 2.38 | Treatment of hypercholesterolaemia with fenofibrate: a review. ( Brown, WV, 1989) |
| "Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects." | 1.56 | Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. ( Buschard, K, 2020) |
| " Clinical prescribing of bexarotene for patients with CTCL requires careful monitoring to allow safe administration of bexarotene at the optimal dose." | 1.39 | U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. ( Azurdia, R; Cowan, R; Eagle, M; Gallop-Evans, E; Graham-Brown, R; Illidge, T; Morris, S; Parry, E; Scarisbrick, JJ; Soran, H; Wachsmuth, R; Wain, EM; Whittaker, S; Wierzbicki, AS, 2013) |
| " The objective of this study was to observe the hypocholesterolemic effect of soybean β-conglycinin (7S protein) alone and combined with fenofibrate and rosuvastatin, two hypolipidemic drugs." | 1.38 | β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats. ( Demonte, A; Ferreira, ES; Neves, VA; Silva, MA, 2012) |
| " The inadequate activity of fenofibrate over the 5 years of the FIELD study might be due to bioavailability problems previously noted with some slow release formulations." | 1.35 | Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer. ( Banfi, F; Falcioni, S; Mombelli, G; Sirtori, CR, 2009) |
| "Fenofibrate treatment (100 mg kg(-1)) produced effects similar to those of Sch B on the hepatic index and lipid levels of hypercholesterolaemic mice." | 1.35 | Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice. ( Dong, H; Fang, HY; Fong, WF; Ko, KM; Pan, SY; Xiang, CJ; Yu, ZL; Zhao, XY, 2008) |
| "Bicyclol treatment for 7 days decreased hepatic triglyceride (5-76%) and total cholesterol (5-48%) levels in mice fed with high-fat/cholesterol diet." | 1.34 | Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. ( Dong, H; Fong, WF; Ko, KM; Pan, SY; Wang, H; Xiang, CJ; Yu, ZL; Zhao, XY, 2007) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 1.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| "Rhabdomyolysis is one of the side effects of these drugs." | 1.31 | [Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate]. ( Dabrowska, M; Duda-Król, W; Jórasz, I; Kusz-Rynkun, A; Polubiec, A, 2000) |
| "Treatment with fenofibrate reduced 7 alpha-hydroxycholesterol concentrations in six patients from 107 +/- 47 ng/ml to 61 +/- 12 ng/ml (p < 0." | 1.29 | Relationship between the serum concentration of 7 alpha-hydroxycholesterol and fecal bile acid excretion in humans. ( Hahn, C; von Bergmann, K, 1996) |
| "Fenofibrate withdrawal was rapidly followed by favorable outcome." | 1.28 | [Fenofibrate-induced acute hepatitis with pseudo-cholangitis]. ( Ducreux, M; Etienne, JP; Lelouch, S; Pelletier, G; Sinico, M, 1992) |
| "Fenofibrate (300 mg/day) was then given for 2 periods of 2 months, each separated by a 2-month period in which only the dietary treatment was continued." | 1.27 | Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states. ( Avogaro, P; Belussi, F; Bittolo Bon, G; Cazzolato, G; Pontoglio, E, 1983) |
| "Fenofibrate was well tolerated and this, together with its effectiveness in lowering lipid values in hypercholesterolaemic children, suggests that it would be useful to achieve primary prevention." | 1.27 | [Action of fenofibrate in hypercholesterolemic children. 18-month follow-up]. ( Chicaud, P; Debry, G; Demange, J; Drouin, P, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (15.05) | 18.7374 |
| 1990's | 26 (27.96) | 18.2507 |
| 2000's | 37 (39.78) | 29.6817 |
| 2010's | 15 (16.13) | 24.3611 |
| 2020's | 1 (1.08) | 2.80 |
| Authors | Studies |
|---|---|
| Cozzi, P | 1 |
| Branzoli, U | 1 |
| Lovisolo, PP | 1 |
| Orsini, G | 1 |
| Carganico, G | 1 |
| Pillan, A | 1 |
| Chiari, A | 1 |
| Buschard, K | 1 |
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
| Preston Mason, R | 1 |
| Zhu, PL | 2 |
| Pan, SY | 6 |
| Zhou, SF | 1 |
| Zhang, Y | 4 |
| Wang, XY | 3 |
| Sun, N | 2 |
| Chu, ZS | 2 |
| Yu, ZL | 6 |
| Ko, KM | 6 |
| Flores-Castillo, C | 1 |
| Zamora-Pérez, JÁ | 1 |
| Carreón-Torres, E | 1 |
| Arzola-Paniagua, A | 1 |
| Aguilar-Salinas, C | 1 |
| López-Olmos, V | 1 |
| Fragoso, JM | 1 |
| Luna-Luna, M | 1 |
| Rodríguez-Pérez, JM | 1 |
| Franco, M | 1 |
| Vargas-Alarcón, G | 1 |
| Pérez-Méndez, Ó | 1 |
| Jia, ZH | 1 |
| Wang, XJ | 1 |
| Rey, J | 1 |
| Poitiers, F | 1 |
| Paehler, T | 1 |
| Brunet, A | 1 |
| DiCioccio, AT | 1 |
| Cannon, CP | 1 |
| Surks, HK | 1 |
| Pinquier, JL | 1 |
| Hanotin, C | 1 |
| Sasiela, WJ | 1 |
| Stroes, E | 1 |
| Guyton, JR | 1 |
| Lepor, N | 1 |
| Civeira, F | 1 |
| Gaudet, D | 1 |
| Watts, GF | 1 |
| Baccara-Dinet, MT | 1 |
| Lecorps, G | 1 |
| Manvelian, G | 1 |
| Farnier, M | 5 |
| Grundy, SM | 1 |
| Vega, GL | 1 |
| Tomassini, JE | 1 |
| Tershakovec, AM | 1 |
| Toutouzas, K | 1 |
| Drakopoulou, M | 1 |
| Skoumas, I | 1 |
| Stefanadis, C | 1 |
| Roth, EM | 1 |
| McKenney, JM | 1 |
| Kelly, MT | 1 |
| Setze, CM | 1 |
| Carlson, DM | 1 |
| Gold, A | 1 |
| Stolzenbach, JC | 1 |
| Williams, LA | 1 |
| Jones, PH | 1 |
| Konrad, RJ | 1 |
| Troutt, JS | 1 |
| Cao, G | 1 |
| Kishimoto, M | 1 |
| Sugiyama, T | 1 |
| Osame, K | 1 |
| Takarabe, D | 1 |
| Okamoto, M | 1 |
| Noda, M | 1 |
| Ferreira, ES | 1 |
| Silva, MA | 1 |
| Demonte, A | 1 |
| Neves, VA | 1 |
| Santos, FA | 1 |
| Frota, JT | 1 |
| Arruda, BR | 1 |
| de Melo, TS | 1 |
| da Silva, AA | 1 |
| Brito, GA | 1 |
| Chaves, MH | 1 |
| Rao, VS | 1 |
| Scarisbrick, JJ | 1 |
| Morris, S | 1 |
| Azurdia, R | 1 |
| Illidge, T | 1 |
| Parry, E | 1 |
| Graham-Brown, R | 1 |
| Cowan, R | 1 |
| Gallop-Evans, E | 1 |
| Wachsmuth, R | 1 |
| Eagle, M | 1 |
| Wierzbicki, AS | 1 |
| Soran, H | 1 |
| Whittaker, S | 1 |
| Wain, EM | 1 |
| Yu, Q | 1 |
| Bortolini, M | 1 |
| Salko, T | 1 |
| Freudenreich, MO | 1 |
| Isaacsohn, JL | 1 |
| Troendle, AJ | 1 |
| Gonasun, L | 1 |
| Nagai, Y | 1 |
| Yamashita, S | 1 |
| Fauchais, AL | 1 |
| Iba Ba, J | 1 |
| Maurage, P | 1 |
| Kyndt, X | 1 |
| Bataille, D | 1 |
| Hachulla, E | 1 |
| Parent, D | 1 |
| Queyrel, V | 1 |
| Lambert, M | 1 |
| Michon Pasturel, U | 1 |
| Hatron, PY | 1 |
| Vanhille, P | 1 |
| Devulder, B | 1 |
| Zhao, SP | 2 |
| Wu, J | 2 |
| Kosoglou, T | 1 |
| Statkevich, P | 1 |
| Fruchart, JC | 3 |
| Pember, LJ | 1 |
| Reyderman, L | 1 |
| Cutler, DL | 1 |
| Guillaume, M | 1 |
| Maxwell, SE | 1 |
| Veltri, EP | 1 |
| Zhang, DQ | 1 |
| Ye, HJ | 1 |
| Liu, L | 1 |
| Li, JQ | 1 |
| Wu, KK | 1 |
| Wu, TJ | 1 |
| Chin, J | 1 |
| Mitnaul, LJ | 1 |
| Hernandez, M | 1 |
| Cai, TQ | 1 |
| Ren, N | 1 |
| Waters, MG | 1 |
| Wright, SD | 1 |
| Cheng, K | 1 |
| Undas, A | 3 |
| Celinska-Löwenhoff, M | 3 |
| Domagala, TB | 1 |
| Iwaniec, T | 1 |
| Dropinski, J | 1 |
| Löwenhoff, T | 1 |
| Szczeklik, A | 3 |
| Mayer, O | 1 |
| Simon, J | 1 |
| Holubec, L | 1 |
| Pikner, R | 1 |
| Trefil, L | 1 |
| Srivastava, RA | 1 |
| Jahagirdar, R | 1 |
| Azhar, S | 1 |
| Sharma, S | 1 |
| Bisgaier, CL | 1 |
| Duriez, P | 1 |
| Corti, R | 1 |
| Osende, J | 1 |
| Hutter, R | 1 |
| Viles-Gonzalez, JF | 1 |
| Zafar, U | 1 |
| Valdivieso, C | 1 |
| Mizsei, G | 1 |
| Fallon, JT | 1 |
| Fuster, V | 1 |
| Badimon, JJ | 1 |
| Potaczek, DP | 1 |
| Stepień, E | 1 |
| Nizankowski, R | 1 |
| Tracz, W | 1 |
| Cheng, AY | 1 |
| Leiter, LA | 1 |
| Yang, R | 1 |
| Dong, H | 3 |
| Xie, W | 1 |
| Nie, Y | 1 |
| Du, L | 1 |
| Cai, G | 1 |
| Gardette, V | 1 |
| Vezzosi, D | 1 |
| Maiza, JC | 1 |
| Montastruc, JL | 1 |
| Olivier, P | 2 |
| Nissen, SE | 1 |
| Nicholls, SJ | 1 |
| Wolski, K | 1 |
| Howey, DC | 1 |
| McErlean, E | 1 |
| Wang, MD | 1 |
| Gomez, EV | 1 |
| Russo, JM | 1 |
| Zvenigorodskaia, LA | 1 |
| Mel'nikova, NV | 1 |
| Bondarenko, EIu | 1 |
| Gerster, JC | 1 |
| Zhao, XY | 2 |
| Xiang, CJ | 2 |
| Wang, H | 1 |
| Fong, WF | 2 |
| Robinson, DM | 1 |
| Keating, GM | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Mombelli, G | 1 |
| Banfi, F | 1 |
| Falcioni, S | 1 |
| Sirtori, CR | 2 |
| Fang, HY | 1 |
| Oztürk, LK | 1 |
| Yarat, A | 1 |
| Emekli, N | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Tréchot, P | 1 |
| Vachon, JM | 1 |
| Chicaud, P | 1 |
| Demange, J | 1 |
| Drouin, P | 5 |
| Debry, G | 1 |
| Canzler, H | 1 |
| Avogaro, P | 1 |
| Bittolo Bon, G | 1 |
| Belussi, F | 1 |
| Pontoglio, E | 1 |
| Cazzolato, G | 1 |
| Wülfert, E | 1 |
| Feher, MD | 1 |
| Foxton, J | 1 |
| Banks, D | 1 |
| Lant, AF | 1 |
| Wray, R | 1 |
| Lepicard, A | 1 |
| Mallat, A | 1 |
| Zafrani, ES | 1 |
| Dhumeaux, D | 1 |
| Schmidt, J | 1 |
| Schmitt, C | 1 |
| Hockwin, O | 1 |
| Paulus, U | 1 |
| von Bergmann, K | 3 |
| Turki, S | 1 |
| Mekaouer, A | 1 |
| Kaabachi, A | 1 |
| Ftouhi, B | 1 |
| Mebazaa, R | 1 |
| Ben Khalifa, F | 1 |
| Devuyst, O | 2 |
| Goffin, E | 2 |
| Pirson, Y | 2 |
| van Ypersele de Strihou, C | 2 |
| Bonnefous, F | 1 |
| Debbas, N | 1 |
| Irvine, A | 1 |
| Chatrenet, P | 1 |
| Regimbeau, C | 1 |
| Ramain, JP | 1 |
| Penot, J | 1 |
| Bruandet, P | 1 |
| Bunte, T | 2 |
| Hahmann, HW | 2 |
| Hellwig, N | 2 |
| Hau, U | 2 |
| Becker, D | 2 |
| Dyckmans, J | 2 |
| Keller, HE | 2 |
| Schieffer, HJ | 2 |
| Caslake, MJ | 1 |
| Packard, CJ | 2 |
| Gaw, A | 1 |
| Murray, E | 1 |
| Griffin, BA | 1 |
| Vallance, BD | 1 |
| Shepherd, J | 3 |
| Sudhop, T | 1 |
| Lütjohann, D | 1 |
| Ratman, C | 1 |
| von Bergmann, J | 1 |
| Hahn, C | 1 |
| Muls, E | 1 |
| Van Gaal, L | 1 |
| Autier, P | 1 |
| Vansant, G | 1 |
| Farmer, JA | 1 |
| Gotto, AM | 1 |
| Ivanova, TN | 1 |
| Poliakova, ED | 1 |
| Olfer'ev, AM | 1 |
| Perova, NV | 1 |
| Bratus', VV | 1 |
| Talaieva, TV | 1 |
| Lomakovs'kyĭ, OM | 1 |
| Tretiak, IV | 1 |
| Radalovs'ka, NV | 1 |
| Krempf, M | 1 |
| Rohmer, V | 1 |
| Issa-Sayegh, M | 1 |
| Corda, C | 1 |
| Sirugue, I | 1 |
| Gerlinger, C | 1 |
| Masseyeff-Elbaz, MF | 1 |
| Duda-Król, W | 1 |
| Jórasz, I | 1 |
| Dabrowska, M | 1 |
| Polubiec, A | 1 |
| Kusz-Rynkun, A | 1 |
| Dejager, S | 1 |
| Tan, CE | 1 |
| Chew, LS | 1 |
| Tai, ES | 1 |
| Chio, LF | 1 |
| Lim, HS | 1 |
| Loh, LM | 1 |
| Kollár, P | 1 |
| Kotolová, H | 1 |
| Necas, J | 1 |
| Karpísek, M | 1 |
| Bartosíková, L | 1 |
| Karesová, P | 1 |
| Risé, P | 1 |
| Pazzucconi, F | 1 |
| Galli, C | 1 |
| Lelouch, S | 1 |
| Pelletier, G | 1 |
| Sinico, M | 1 |
| Ducreux, M | 1 |
| Etienne, JP | 1 |
| Bard, JM | 2 |
| Parra, HJ | 2 |
| Camare, R | 2 |
| Luc, G | 2 |
| Ziegler, O | 3 |
| Dachet, C | 3 |
| Bruckert, E | 2 |
| Douste-Blazy, P | 3 |
| Jacotot, B | 3 |
| Huff, MW | 1 |
| Agheli, N | 1 |
| Zimetbaum, P | 1 |
| Frishman, WH | 1 |
| Kahn, S | 1 |
| Fricker, J | 1 |
| De Gennes, JL | 1 |
| Keller, U | 2 |
| Stohler, R | 1 |
| Riesen, WF | 1 |
| Brown, WV | 2 |
| Turpin, G | 1 |
| Knopp, RH | 1 |
| Walden, CE | 1 |
| Warnick, GR | 1 |
| Albers, JJ | 1 |
| Ginsberg, J | 1 |
| McGinnis, BM | 1 |
| Plancke, MO | 1 |
| Clavey, V | 1 |
| Marzin, D | 1 |
| Mellies, MJ | 1 |
| Stein, EA | 1 |
| Khoury, P | 1 |
| Lamkin, G | 1 |
| Glueck, CJ | 1 |
| Kulejewski, L | 1 |
| Giec, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subje[NCT01723735] | Phase 1 | 79 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin[NCT02023879] | Phase 3 | 233 participants (Actual) | Interventional | 2013-12-16 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patie[NCT00092157] | Phase 3 | 571 participants (Actual) | Interventional | 2002-05-01 | Completed | ||
| An 8-Week, Multicenter, Randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects With Hypercholesterolemia[NCT00812955] | Phase 3 | 474 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia[NCT00133380] | Phase 2 | 300 participants | Interventional | 2005-07-31 | Completed | ||
| PPAR Alpha: A Phase 2 Dose-Finding and Safety Study for Atherogenic Dyslipidemia by Eli Lilly[NCT00116519] | Phase 2 | 300 participants | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 2.6 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 5.9 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 7.6 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.4 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 8.2 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 10.0 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 7.0 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -38.4 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -31.3 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 7.7 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -41.2 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -40.9 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 7.5 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -39.7 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -38.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.6 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -54.1 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -55.0 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.2 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -50.8 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -41.7 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.6 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -51.5 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -44.8 |
Adjusted Least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 4.7 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator) | -53.5 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -51.7 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 5.1 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -55.3 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -54.6 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment and assigning a weight of 0.25 for Week 9, 10, 11 and 12 time points. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.2 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -53.6 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -52.3 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Mean) |
|---|---|
| Placebo Q2W | 2.1 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -11.3 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -3.0 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Mean) |
|---|---|
| Placebo Q2W | 1.1 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -10.6 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -9.2 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | -0.8 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 6.8 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 8.6 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | -2.4 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 7.4 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 7.7 |
Adjusted means and standard errors at Week 12 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Mean) |
|---|---|
| Placebo Q2W | 2.2 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -16.5 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -5.7 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Mean) |
|---|---|
| Placebo Q2W | 4.1 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -21.8 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -15.5 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.0 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -43.4 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -34.9 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 4.8 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -45.3 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -44.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 5.0 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -46.9 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -46.7 |
Adjusted LS means and standard errors at Week 12 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 1.8 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -32.6 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -24.5 |
Adjusted LS means and standard errors at Week 24 from MMRM including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Placebo Q2W | 3.0 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | -34.0 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | -32.3 |
Adjusted percentages at Week 24 from LOCF approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Q2W | 0.0 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 61.7 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 50.9 |
Adjusted percentages at Week 24 from last observation carried forward (LOCF) approach including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment. (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Q2W | 0.0 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 60.0 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 50.0 |
"Moderate CV risk: 10-year fatal cardiovascular disease (CVD) risk Systemic Coronary Risk Evaluation (SCORE) ≥1 and <5%.~High CV risk: 10-year fatal CVD risk SCORE ≥5% or moderate chronic kidney disease or type 1 or type 2 diabetes mellitus without target organ damage or familial hypercholesterolemia.~Very high CV risk: history of documented coronary heart disease, ischemic stroke, peripheral artery disease, transient ischemic attack, abdominal aortic aneurysm, or carotid artery occlusion >50% without symptoms; carotid endarterectomy or carotid artery stent procedure; renal artery stenosis, or renal artery stent procedure; or type 1 or type 2 diabetes mellitus with target organ damage.~Adjusted percentages at Week 24 were obtained from a multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included." (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Q2W | 1.8 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 70.3 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 63.9 |
Adjusted percentages at Week 24 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection). (NCT02023879)
Timeframe: From Baseline to Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo Q2W | 1.8 |
| Alirocumab 75 mg Q2W/Up to 150 mg Q2W | 72.7 |
| Alirocumab 150 mg Q4W/Up to 150 mg Q2W | 67.7 |
Mean percent changes (and standard deviations) observed during the open-label extension period are provided. (NCT02023879)
Timeframe: Baseline, Week 32, 36, 48, 72, 96, 120, 144 and Week 168
| Intervention | percent change (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 32 | Week 36 | Week 48 | Week 72 | Week 96 | Week 120 | Week 144 | Week 168 | |
| Alirocumab 150 mg Q4W (After Alirocumab 150 Q4W/Up 150 Q2W) | -46.9 | -43.1 | -48.7 | -52.3 | -46.8 | -51.8 | -49.4 | -60.0 |
| Alirocumab 150 mg Q4W (After Placebo Q2W) | -37.3 | -36.1 | -46.5 | -50.8 | -49.8 | -50.6 | -52.7 | -47.8 |
| Alirocumab 150 mg QW4 (After Alirocumab 75 Q2W/Up 150 Q2W) | -41.1 | -39.2 | -49.2 | -53.7 | -52.8 | -53.7 | -48.7 | -66.2 |
"The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following two treatment groups:~ABT-143 capsules 20/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set." (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | -32.8 |
| ABT-143 Capsules 20/135 mg | -47.2 |
The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following treatment groups, ABT-143 capsules 10/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | -32.8 |
| ABT-143 Capsules 10/135 mg | -46.0 |
The mean percent change from Baseline to the Final Visit in low-density lipoprotein cholesterol, comparing the following treatment groups, ABT-143 capsules 5/135 milligrams versus simvastatin capsules 40 milligrams for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | -32.8 |
| ABT-143 Capsules 5/135 mg | -38.9 |
The ABT-143 capsules 20/135 milligram, ABT-143 capsules 10/135 milligram, and ABT-143 capsules 5/135 milligram groups were compared to the simvastatin capsules 40 milligram group for mean percent change in high-density lipoprotein cholesterol from Baseline to the Final Visit for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Mean) |
|---|---|
| Simvastatin Capsules 40 mg | 9.6 |
| ABT-143 Capsules 5/135 mg | 16.2 |
| ABT-143 Capsules 10/135 mg | 14.0 |
| ABT-143 Capsules 20/135 mg | 15.7 |
The ABT-143 capsules 20/135 milligram, ABT-143 capsules 10/135 milligram, and ABT-143 capsules 5/135 milligram groups were compared to the simvastatin capsules 40 milligram group for median percent change in triglycerides from Baseline to the Final Visit for the full analysis set. (NCT00812955)
Timeframe: Baseline to 8 weeks
| Intervention | percent change (Median) |
|---|---|
| Simvastatin Capsules 40 mg | -20.8 |
| ABT-143 Capsules 5/135 mg | -42.7 |
| ABT-143 Capsules 10/135 mg | -44.6 |
| ABT-143 Capsules 20/135 mg | -50.0 |
12 reviews available for fenofibrate and Hypercholesterolemia
| Article | Year |
|---|---|
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosa | 2019 |
Advancing therapy for hypercholesterolemia.
Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins | 2010 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Di | 2003 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
Topics: Adult; Antihypertensive Agents; Diabetes Complications; Evidence-Based Medicine; Fenofibrate; Health | 2006 |
[Involvement of the foot in metabolic diseases].
Topics: Achilles Tendon; Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Apatites; Chon | 2007 |
Colesevelam: a review of its use in hypercholesterolemia.
Topics: Allylamine; Anticholesteremic Agents; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Com | 2007 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Huma | 1993 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; | 1991 |
Treatment of hypercholesterolaemia with fenofibrate: a review.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Fenofibrate; Humans; Hypercholesterolemia; Propiona | 1989 |
Focus on fenofibrate.
Topics: Anticholesteremic Agents; Cholesterol; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 1988 |
27 trials available for fenofibrate and Hypercholesterolemia
| Article | Year |
|---|---|
Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Human | 2016 |
Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholester | 2016 |
Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Hu | 2009 |
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug | 2010 |
Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Blood Glucose; Cholesterol; Diabetes Mellitus, Ty | 2011 |
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.
Topics: Adult; Azetidines; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Hum | 2004 |
Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Antithrombins; beta-Thromboglobulin; Blood Coagu | 2005 |
Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Endo | 2006 |
Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients.
Topics: Biomarkers; C-Reactive Protein; CD40 Ligand; Female; Fenofibrate; Genetic Predisposition to Disease; | 2006 |
Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury.
Topics: Adult; Aged; Angiogenic Proteins; Anticholesteremic Agents; Becaplermin; Bleeding Time; CD40 Ligand; | 2006 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydr | 2007 |
[Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
Topics: Carbohydrate Metabolism; Clofibric Acid; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 2007 |
[Therapeutic trial of simvastatin versus fenofibrate in primary hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Huma | 1994 |
Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Female; Fe | 1994 |
[Effect of micronized fenofibrate (lipantyl-200M) on synthesis of cholesterol in peripheral blood lymphocytes of patients with ischemic heart disease and hyperlipidemia].
Topics: Adult; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hyperc | 1998 |
Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins B; Chemistry, Pharmaceutical; Cholesterol; Cholesterol, LDL; Dose-Respo | 2000 |
Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study Group.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Cholesterol, LDL; | 2000 |
Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; Blood Glucose; Blood Pressure; Cholesterol | 2001 |
A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Female; Fenofibrate | 1992 |
Lipoprotein particle analysis comparing simvastatin and fenofibrate.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipop | 1991 |
Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol Esters; Double-Blind Method; Fatty Acids; Female; | 1991 |
Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Double-Blind Method | 1990 |
[The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; C | 1990 |
Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apo | 1989 |
Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipopro | 1987 |
Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia.
Topics: Apolipoproteins; Clinical Trials as Topic; Diet; Double-Blind Method; Female; Fenofibrate; Humans; H | 1987 |
[Evaluation of the effectiveness of procetofen in the treatment of hypercholesterolemia].
Topics: Adult; Aged; Clinical Trials as Topic; Female; Fenofibrate; Humans; Hypercholesterolemia; Male; Midd | 1985 |
54 other studies available for fenofibrate and Hypercholesterolemia
| Article | Year |
|---|---|
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins.
Topics: Alcohols; Animals; Cholesterol; Enzyme Induction; Hypercholesterolemia; Hypolipidemic Agents; Imidaz | 1986 |
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.
Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
The Effect of Hypolipidemic Agents on Thyroid Autoimmunity in Women with Hashimoto's Thyroiditis Treated with Levothyroxine and Selenomethionine.
Topics: Adult; Autoantibodies; Autoimmunity; Female; Fenofibrate; Hashimoto Disease; Humans; Hydroxymethylgl | 2018 |
Effects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice.
Topics: Animals; Combined Modality Therapy; Dietary Supplements; Dose-Response Relationship, Drug; Drugs, Ch | 2015 |
Atorvastatin and fenofibrate combination induces the predominance of the large HDL subclasses and increased apo AI fractional catabolic rates in New Zealand white rabbits with exogenous hypercholesterolemia.
Topics: Animals; Apolipoprotein A-I; Aryldialkylphosphatase; Atorvastatin; Blood Glucose; Cholesterol, HDL; | 2015 |
A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Blood Glucose; Body Weight; Cholesterol, Dietary; | 2015 |
Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Fenofibrate; Humans; Hyd | 2011 |
β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.
Topics: Animals; Anticholesteremic Agents; Antigens, Plant; Cholesterol; Diet, High-Fat; Dietary Proteins; D | 2012 |
Antihyperglycemic and hypolipidemic effects of α, β-amyrin, a triterpenoid mixture from Protium heptaphyllum in mice.
Topics: Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diet, High-Fat; Drug Discovery | 2012 |
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
Topics: Adult; Amylases; Anticarcinogenic Agents; Bexarotene; Blood Cell Count; Blood Glucose; Cholesterol, | 2013 |
Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity.
Topics: Animals; Cyclooctanes; Diet; Drugs, Chinese Herbal; Fenofibrate; Fruit; Hypercholesterolemia; Hypoli | 2012 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female | 2003 |
[Polymyositis induced or associated with lipid-lowering drugs: five cases].
Topics: Aged; Antibodies, Antinuclear; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 2004 |
Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Body Weight; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, | 2004 |
Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit.
Topics: Adipocytes; Animals; CD36 Antigens; Cells, Cultured; Fenofibrate; Hypercholesterolemia; Hypolipidemi | 2004 |
Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiop | 2005 |
Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Topics: Adiposity; Animals; Aorta; Coronary Artery Disease; Diet, Atherogenic; Energy Metabolism; Fenofibrat | 2006 |
Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI.
Topics: Animals; Atherosclerosis; Fenofibrate; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Mag | 2007 |
Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice.
Topics: Animals; Bile Acids and Salts; Biphenyl Compounds; Cholesterol; Cholesterol, Dietary; Disease Models | 2006 |
Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Chemical and Drug Induced Liver Injury; Cholest | 2007 |
Gynecomastia associated with fenofibrate.
Topics: Fenofibrate; Gynecomastia; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged | 2007 |
Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.
Topics: Analysis of Variance; Animals; Bile Acids and Salts; Biphenyl Compounds; Cholesterol; Cholesterol, D | 2007 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Female; Fenofibrate; Follow-Up Studies; Hum | 2009 |
Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.
Topics: Animals; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Cyclooctanes; Disease Models, Anim | 2008 |
Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, LDL; Eating; Fenofibrate; Hypercholesterolemia; Hypo | 2007 |
[Fenofibrates and gynaecomastia].
Topics: Fenofibrate; Gynecomastia; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged | 2008 |
[Hepatitis caused by procetofen].
Topics: Chemical and Drug Induced Liver Injury; Cholestyramine Resin; Female; Fenofibrate; gamma-Glutamylcyc | 1980 |
[Action of fenofibrate in hypercholesterolemic children. 18-month follow-up].
Topics: Child; Cholesterol; Female; Fenofibrate; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Prop | 1984 |
[Drug therapy of hypercholesterinemias (author's transl)].
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; | 1980 |
Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Diet; Female; Fenofibrate; Humans; Hypercholesterolemia; | 1983 |
[How does fenofibrate exert its cholesterol-lowering effect? (author's transl)].
Topics: Animals; Cholesterol; Cholesterol Esters; Depression, Chemical; Fenofibrate; Humans; Hypercholestero | 1980 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Ki | 1995 |
[Chronic lesion of the interlobular bile ducts induced by fenofibrate].
Topics: Cholestasis, Intrahepatic; Chronic Disease; Female; Fenofibrate; Humans; Hypercholesterolemia; Liver | 1994 |
Ocular drug safety and HMG-CoA-reductase inhibitors.
Topics: Color Perception; Contrast Sensitivity; Eye; Female; Fenofibrate; Humans; Hydroxymethylglutaryl CoA | 1994 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hy | 1994 |
Creatinine rise after fibrate therapy in renal graft recipients.
Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterol | 1993 |
[Chronic active cirrhogenic hepatitis induced by fenofibrate].
Topics: Chemical and Drug Induced Liver Injury, Chronic; Female; Fenofibrate; Hepatitis, Chronic; Humans; Hy | 1993 |
Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients.
Topics: Coronary Angiography; Coronary Artery Disease; Female; Fenofibrate; Humans; Hypercholesterolemia; Li | 1993 |
Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.
Topics: Aged; Apolipoproteins; Female; Fenofibrate; Humans; Hypercholesterolemia; Kinetics; Lipoproteins, LD | 1993 |
Differences in the response of serum lipoproteins to fenofibrate between women and men with primary hypercholesterolaemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Humans; Hypercholestero | 1996 |
Relationship between the serum concentration of 7 alpha-hydroxycholesterol and fecal bile acid excretion in humans.
Topics: Acyl Coenzyme A; Adolescent; Adult; Aged; Bile Acids and Salts; Child; Child, Preschool; Feces; Fema | 1996 |
LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Fenofibrate; Humans; Hypercholesterolemia; Hypolipi | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholes | 1997 |
[Modified lipoproteins--their types and role in atherogenesis].
Topics: Adult; Animals; Arteriosclerosis; Child; Child, Preschool; Chronic Disease; Coronary Artery Disease; | 2000 |
[Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate].
Topics: Aged; Creatine Kinase; Creatinine; Female; Fenofibrate; Humans; Hypercholesterolemia; Hypolipidemic | 2000 |
[Experimental study of resveratrol and flavonoids in red wine with regard to their possible hypolipemic effects].
Topics: Animals; Antioxidants; Cholesterol; Fenofibrate; Flavonoids; Hypercholesterolemia; Hypolipidemic Age | 2000 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
Statins enhance arachidonic acid synthesis in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Arachidonic Acid; Cholesterol; Cholesterol, LDL; Diet, Reducing; Fatty Aci | 2001 |
[Fenofibrate-induced acute hepatitis with pseudo-cholangitis].
Topics: Abdominal Pain; Acute Disease; Aged; Chemical and Drug Induced Liver Injury; Eosinophilia; Fenofibra | 1992 |
[Quantitative coronary angiography: progression and regression of coronary stenoses--an intervention study with fenofibrate].
Topics: Angioplasty, Balloon, Coronary; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality T | 1991 |
Fibrates and HMG-CoA reductase inhibitors.
Topics: Anticholesteremic Agents; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi | 1991 |
[Diets and drugs to lower blood cholesterol].
Topics: Cholesterol; Cholestyramine Resin; Dietary Fats; Fatty Acids, Monounsaturated; Fatty Acids, Unsatura | 1989 |
Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamsters. Influence of fenofibrate.
Topics: Animals; Cholesterol; Cricetinae; Female; Fenofibrate; Hypercholesterolemia; Lipid Metabolism; Lipid | 1988 |